Company Overview

Driven to innovate and with a proven record of double-digit growth, Ceva is one of the fastest growing top 10 animal healthcare companies. Our vision reaches far beyond animal health and welfare.

Ceva Santé Animale was the fastest growing Top 10 veterinary health company through our first 10 years of existence*. We now rank as the ninth largest animal health group globally – and we were only founded in 1999! Our expertise centres on the two fields of pharmacology and biology, where we have dedicated teams that aim to meet the specific demands of the companion animal, poultry, ruminant and swine sectors. We continually strive to find better solutions to existing and emerging diseases which will in turn improve animal health and productivity.

Our care extends beyond animal health and welfare. These days, a staggering 75% of all emerging human infectious diseases are of animal origin. Ceva is involved in the fight against the spread of infectious disease that can be transmitted from wild or domestic animals and birds to humans – diseases known as zoonoses, which include avian flu, brucellosis and Q-fever.

Ceva is a visible supporter of and contributor to various welfare and social programmes all over the world. Our work ranges from researching, developing, producing and supplying animal health products to the poorest livestock owners in the world, of which our SOS (Stamp Out Sleeping sickness) programme in Uganda is a good example; to supplying the UK’s largest dog welfare charity with Dog Appeasing Pheromone (DAP) collars, to help make the lives of dogs in shelter less stressful.

Ceva successfully combines profitability with long-term growth.

To take better account of the geographic realities and segmentation of our customers, as well as the specificities of our key countries, we will reduce the number of zones from 6 to 5.

  • The North American Zone will be extended to include Australia and New Zealand (Pacific)
  • The European Zone will bring together all the European countries (with the exception of the Ukraine) and also include Norway, The Balkans and Switzerland
  • The AMEET Zone will extend to include Russia, the Ukraine and Turkey
  • The Latin America Zone remains unchanged
  • The Asia-Pacific Zone becomes Asia Zone

We are truly global, based in 42 countries and working across more than 110. We have 13 R&D centres, 21 production sites and more than 3,500 employees worldwide.

*Source: Vetnosis, CAGR period 1999-2009

Back to top